SCHEMBL298903

SCHEMBL298903

N[C@H](Cc1ccccc1Cl)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.58
ALPI P09923 1/20 0.58
PTGS1 P23219 1/20 0.58
XIAP P98170 1/20 0.58
SLC7A5 Q01650 1/20 0.58
NOS3 P29474 3/20 0.57
NOS1 P29475 3/20 0.57
NOS2 P35228 3/20 0.57
PPARG P37231 1/20 0.53
PPARA Q07869 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 3/20 0.51
KDM4E B2RXH2 2/20 0.51
LMNA P02545 2/20 0.51
BLM P54132 2/20 0.51
PMP22 Q01453 2/20 0.51
HIF1A Q16665 2/20 0.51
MPO P05164 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35491891 1.00 PKM (0.58) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL43977 1.00 PKM (0.58) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL29351556 1.00 PKM (0.58) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL43976 1.00 PKM (0.58) PKMALPIPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL21904241 0.98 PKM (0.56) PKMALPIPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL1514957 0.98 PKM (0.56) PKMALPIPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL27479478 0.98 PKM (0.56) PKMALPIPTGS1XIAPSLC7A5
Methyl Alcohol SCHEMBL28880032 0.96 NOS3 (0.56) PKMALPIPTGS1XIAPSLC7A5
Methyl Alcohol SCHEMBL29067173 0.95 NOS3 (0.55) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL13971424 0.86 SLC7A5 (0.69) PKMALPIPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4696699-A1 ? OPIOID RECEPTOR AGONIST AND USE THEREOF Chengdu Aoda Biotechnology Co., Ltd. (CN) 2026-02-18 EP claimed
EP-4696700-A1 LONG-ACTING K-OPIOID RECEPTOR AGONIST Chengdu Aoda Biotechnology Co., Ltd (CN) 2026-02-18 EP claimed
CN-119899240-A Kappa opioid receptor agonist and application thereof 成都奥达生物科技有限公司 2025-04-29 CN claimed
CN-119390765-A Kappa opioid receptor agonist and application thereof 成都奥达生物科技有限公司 2025-02-07 CN claimed
WO-2024212865-A1 κ OPIOID RECEPTOR AGONIST AND USE THEREOF 成都奥达生物科技有限公司 2024-10-17 WO claimed
WO-2024212866-A1 LONG-ACTING K-OPIOID RECEPTOR AGONIST 成都奥达生物科技有限公司 2024-10-17 WO claimed
CN-118772231-A Kappa opioid receptor agonist and application thereof 成都奥达生物科技有限公司 2024-10-15 CN claimed
US-20240008483-A1 COMPOSITION FOR MOLD REMEDIATION MOLD GUARD INC. (CA) 2024-01-11 US claimed
CN-116997648-A Composition for mould repair 霉菌防护有限公司 2023-11-03 CN claimed
EP-4244364-A1 COMPOSITION FOR MOLD REMEDIATION Mold Guard Inc. (CA) 2023-09-20 EP claimed
US-10344054-B2 Angiotensin-1-receptor antagonists FERRING B.V. (NL) 2019-07-09 US claimed
EP-3464324-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS Ferring B.V. (NL) 2019-04-10 EP claimed
CN-109311942-A Angiotensin-1 receptor antagonists 辉凌公司 2019-02-05 CN claimed
CN-105866299-B The non-targeted metabolism group sample pretreating method of plant based on GC-MS 上海鹿明生物科技有限公司 2018-11-13 CN claimed
WO-2017207760-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING B.V. (NL) 2017-12-07 WO claimed
US-20170349629-A1 Angiotensin-1-Receptor Antagonists FERRING B.V. (NL) 2017-12-07 US claimed
US-9695191-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2017-07-04 US claimed
CN-105866299-A GC-MS-based plant non-targeted metabolomics sample pretreatment method 上海青鹿投资有限公司 2016-08-17 CN claimed
EP-2462147-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2014-11-12 EP claimed
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-08-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349629-A1 Angiotensin-1-Receptor Antagonists AGTR1, AGTR2, REN PKM 3664/4885ALPI 3555/4885PTGS1 122/4885
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS HTR2B, MC1R, HTR1A PKM 2553/4885ALPI 2014/4885PTGS1 109/4885
US-10344054-B2 Angiotensin-1-receptor antagonists AGTR1, AGTR2, AGT PKM 3198/4885ALPI 3362/4885PTGS1 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.